Lysosomal storage diseases (LSD) include a wide range of different disorders with variable degrees of respiratory system involvement. The purpose of this narrative review is to treat the different types of respiratory manifestations in LSD, with particular attention being paid to the main molecular pathways known so far to be involved in the pathogenesis of the disease. A literature search was conducted using the Medline/PubMed and EMBASE databases to identify studies, from 1968 through to November 2018, that investigated the respiratory manifestations and molecular pathways affected in LSD. Pulmonary involvement includes interstitial lung disease in Gaucher's disease and Niemann-Pick disease, obstructive airway disease in Fabry disease and ventilatory disorders with chronic respiratory failure in Pompe disease due to diaphragmatic and abdominal wall muscle weakness. In mucopolysaccharidosis and mucolipidoses, respiratory symptoms usually manifest early in life and are secondary to anatomical malformations, particularly of the trachea and chest wall, and to accumulation of glycosaminoglycans in the upper and lower airways, causing, for example, obstructive sleep apnea syndrome. Although the molecular pathways involved vary, ranging from lipid to glycogen and glycosaminoglycans accumulation, some clinical manifestations and therapeutic approaches are common among diseases, suggesting that lysosomal storage and subsequent cellular toxicity are the common endpoints.

Faverio, P., Stainer, A., De Giacomi, F., Gasperini, S., Motta, S., Canonico, F., et al. (2019). Molecular Pathways and Respiratory Involvement in Lysosomal Storage Diseases. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 20(2), 327 [10.3390/ijms20020327].

Molecular Pathways and Respiratory Involvement in Lysosomal Storage Diseases

Faverio, Paola
;
Stainer, Anna;De Giacomi, Federica;Motta, Serena;Pieruzzi, Federico;Monzani, Anna;Pesci, Alberto;Biondi, Andrea
2019

Abstract

Lysosomal storage diseases (LSD) include a wide range of different disorders with variable degrees of respiratory system involvement. The purpose of this narrative review is to treat the different types of respiratory manifestations in LSD, with particular attention being paid to the main molecular pathways known so far to be involved in the pathogenesis of the disease. A literature search was conducted using the Medline/PubMed and EMBASE databases to identify studies, from 1968 through to November 2018, that investigated the respiratory manifestations and molecular pathways affected in LSD. Pulmonary involvement includes interstitial lung disease in Gaucher's disease and Niemann-Pick disease, obstructive airway disease in Fabry disease and ventilatory disorders with chronic respiratory failure in Pompe disease due to diaphragmatic and abdominal wall muscle weakness. In mucopolysaccharidosis and mucolipidoses, respiratory symptoms usually manifest early in life and are secondary to anatomical malformations, particularly of the trachea and chest wall, and to accumulation of glycosaminoglycans in the upper and lower airways, causing, for example, obstructive sleep apnea syndrome. Although the molecular pathways involved vary, ranging from lipid to glycogen and glycosaminoglycans accumulation, some clinical manifestations and therapeutic approaches are common among diseases, suggesting that lysosomal storage and subsequent cellular toxicity are the common endpoints.
Articolo in rivista - Articolo scientifico
Scientifica
Fabry disease; Gaucher’s disease; lung involvement; lysosomal storage diseases; mucolipidoses; mucopolysaccharidosis; Niemann-Pick disease; Pompe disease; Catalysis; Molecular Biology; Spectroscopy; Computer Science Applications1707 Computer Vision and Pattern Recognition; Physical and Theoretical Chemistry; Organic Chemistry; Inorganic Chemistry
English
Faverio, P., Stainer, A., De Giacomi, F., Gasperini, S., Motta, S., Canonico, F., et al. (2019). Molecular Pathways and Respiratory Involvement in Lysosomal Storage Diseases. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 20(2), 327 [10.3390/ijms20020327].
Faverio, P; Stainer, A; De Giacomi, F; Gasperini, S; Motta, S; Canonico, F; Pieruzzi, F; Monzani, A; Pesci, A; Biondi, A
File in questo prodotto:
File Dimensione Formato  
10281-219469.pdf

accesso aperto

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Dimensione 1.92 MB
Formato Adobe PDF
1.92 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10281/219469
Citazioni
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 14
Social impact